{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:51:14Z","timestamp":1783561874303,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40273-024-01465-w","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:06:26Z","timestamp":1736589986000},"page":"375-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Projections of Public Spending on Pharmaceuticals: A Review of Methods"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-1250","authenticated-orcid":false,"given":"Irina","family":"Odnoletkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-8880","authenticated-orcid":false,"given":"Patrice X.","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-8916","authenticated-orcid":false,"given":"Stephan","family":"Devriese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-8950","authenticated-orcid":false,"given":"Irina","family":"Cleemput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"1465_CR1","unstructured":"OECD. Health at a Glance 2023. 2023."},{"key":"1465_CR2","unstructured":"NIHDI Department of Pharmaceutical Policy\u2014Medical Care Service. Monitoring of Reimbursement Significant Expenses (MORSE) report 2020. 2020."},{"issue":"6","key":"1465_CR3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jval.2022.12.014","volume":"26","author":"C Iglesias-L\u00f3pez","year":"2023","unstructured":"Iglesias-L\u00f3pez C, Agust\u00ed A, Vallano A, Obach M. Financing and reimbursement of approved advanced therapies in several European countries. Value Health. 2023;26(6):841\u201353.","journal-title":"Value Health"},{"key":"1465_CR4","unstructured":"Improving Forecasting of Pharmaceutical Spending\u2014Insights from 23 OECD and EU Countries. Analytical Report. OECD; 2019."},{"issue":"13\u201315","key":"1465_CR5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1080\/00036846.2011.633895","volume":"45","author":"SP Thiebaut","year":"2013","unstructured":"Thiebaut SP, Barnay T, Ventelou B. Ageing, chronic conditions and the evolution of future drugs expenditure: a five-year micro-simulation from 2004 to 2029. Appl Econ. 2013;45(13\u201315):1663\u201372.","journal-title":"Appl Econ"},{"issue":"8","key":"1465_CR6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1377\/hlthaff.2015.0600","volume":"34","author":"SP Keehan","year":"2015","unstructured":"Keehan SP, Cuckler GA, Sisko AM, Madison AJ, Smith SD, Stone DA, et al. National health expenditure projections, 2014\u201324: spending growth faster than recent trends. Health Aff. 2015;34(8):1407\u201317.","journal-title":"Health Aff"},{"key":"1465_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/1472-6963-14-477","volume":"14","author":"A Conway","year":"2014","unstructured":"Conway A, Kenneally M, Woods N, Thummel A, Ryan M. The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026. BMC Health Serv Res. 2014;14:477.","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"1465_CR8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40273-013-0082-1","volume":"31","author":"P O'Neill","year":"2013","unstructured":"O\u2019Neill P, Mestre-Ferrandiz J, Puig-Peiro R, Sussex J. Projecting expenditure on medicines in the UK NHS. Pharmacoeconomics. 2013;31(10):933\u201357.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1465_CR9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-019-00533-z","volume":"18","author":"PM Murray","year":"2020","unstructured":"Murray PM, Shalaby YA, Ieraci L, Borg E, Sniekers D, Esensoy AV. Forecasting Ontario oncology drug expenditures: a hybrid approach to improving accuracy. Appl Health Econ Health Policy. 2020;18(1):127\u201337.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1\u20132","key":"1465_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1017\/S0266462315000100","volume":"31","author":"C Packer","year":"2015","unstructured":"Packer C, Simpson S, de Almeida RT. Euroscan international network member agencies: their structure, processes, and outputs. Int J Technol Assess Health Care. 2015;31(1\u20132):78\u201385.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"1465_CR11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2146\/ajhp120759","volume":"70","author":"JM Hoffman","year":"2013","unstructured":"Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, et al. Projecting future drug expenditures in US Nonfederal hospitals and clinics-2013. Am J Health Syst Pharm. 2013;70(6):525\u201339.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"1465_CR12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2146\/ajhp130767","volume":"71","author":"GT Schumock","year":"2014","unstructured":"Schumock GT, Li EC, Suda KJ, Hines E, Matusiak LM, Hunkler RJ, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm. 2014;71(6):482\u201399.","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"1465_CR13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2146\/ajhp140849","volume":"72","author":"GT Schumock","year":"2015","unstructured":"Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2015. Am J Health Syst Pharm. 2015;72(9):717\u201336.","journal-title":"Am J Health Syst Pharm"},{"issue":"14","key":"1465_CR14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2146\/ajhp160205","volume":"73","author":"GT Schumock","year":"2016","unstructured":"Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2016. Am J Health Syst Pharm. 2016;73(14):1058\u201375.","journal-title":"Am J Health Syst Pharm"},{"issue":"15","key":"1465_CR15","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2146\/ajhp170164","volume":"74","author":"GT Schumock","year":"2017","unstructured":"Schumock GT, Li EC, Wiest MD, Suda KJ, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2017. Am J Health Syst Pharm. 2017;74(15):1158\u201373.","journal-title":"Am J Health Syst Pharm"},{"issue":"14","key":"1465_CR16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2146\/ajhp180138","volume":"75","author":"GT Schumock","year":"2018","unstructured":"Schumock GT, Stubbings J, Wiest MD, Li EC, Suda KJ, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2018. Am J Health Syst Pharm. 2018;75(14):1023\u201338.","journal-title":"Am J Health Syst Pharm"},{"issue":"15","key":"1465_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/ajhp\/zxz109","volume":"76","author":"GT Schumock","year":"2019","unstructured":"Schumock GT, Stubbings J, Hoffman JM, Wiest MD, Suda KJ, Rim MH, et al. National trends in prescription drug expenditures and projections for 2019. Am J Health Syst Pharm. 2019;76(15):1105\u201321.","journal-title":"Am J Health Syst Pharm"},{"issue":"15","key":"1465_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/ajhp\/zxaa116","volume":"77","author":"EM Tichy","year":"2020","unstructured":"Tichy EM, Schumock GT, Hoffman JM, Suda KJ, Rim MH, Tadrous M, et al. National trends in prescription drug expenditures and projections for 2020. Am J Health Syst Pharm. 2020;77(15):1213\u201330.","journal-title":"Am J Health Syst Pharm"},{"issue":"14","key":"1465_CR19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ajhp\/zxab160","volume":"78","author":"EM Tichy","year":"2021","unstructured":"Tichy EM, Hoffman JM, Suda KJ, Rim MH, Tadrous M, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2021. Am J Health Syst Pharm. 2021;78(14):1294\u2013308.","journal-title":"Am J Health Syst Pharm"},{"issue":"14","key":"1465_CR20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ajhp\/zxac102","volume":"79","author":"EM Tichy","year":"2022","unstructured":"Tichy EM, Hoffman JM, Suda KJ, Rim MH, Tadrous M, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022;79(14):1158\u201372.","journal-title":"Am J Health Syst Pharm"},{"issue":"14","key":"1465_CR21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajhp\/zxad086","volume":"80","author":"EM Tichy","year":"2023","unstructured":"Tichy EM, Hoffman JM, Tadrous M, Rim MH, Suda KJ, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2023. Am J Health Syst Pharm. 2023;80(14):899\u2013913.","journal-title":"Am J Health Syst Pharm"},{"key":"1465_CR22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ajhp\/zxae105","volume":"81","author":"EM Tichy","year":"2024","unstructured":"Tichy EM, Hoffman JM, Tadrous M, Rim MH, Cuellar S, Clark JS, et al. National trends in prescription drug expenditures and projections for 2024. Am J Health Syst Pharm. 2024;81:583\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"19","key":"1465_CR23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2146\/ajhp140850","volume":"72","author":"PL Hartke","year":"2015","unstructured":"Hartke PL, Vermeulen LC, Hoffman JM, Shah ND, Doloresco F, Suda KJ, et al. Accuracy of annual prescription drug expenditure forecasts in AJHP. Am J Health Syst Pharm. 2015;72(19):1642\u20138.","journal-title":"Am J Health Syst Pharm"},{"key":"1465_CR24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1472-6963-10-128","volume":"10","author":"B Wettermark","year":"2010","unstructured":"Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010;10:128.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1465_CR25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12913-020-05170-0","volume":"20","author":"L Linn\u00e9r","year":"2020","unstructured":"Linn\u00e9r L, Eriksson I, Persson M, Wettermark B. Forecasting drug utilization and expenditure: ten years of experience in Stockholm. BMC Health Serv Res. 2020;20(1):410.","journal-title":"BMC Health Serv Res"},{"key":"1465_CR26","doi-asserted-by":"crossref","first-page":"23740","DOI":"10.3402\/jmahp.v2.23740","volume":"2","author":"C Remuzat","year":"2014","unstructured":"Remuzat C, Urbinati D, Kornfeld A, Vataire AL, Cetinsoy L, Aballea S, et al. Pharmaceutical expenditure forecast model to support health policy decision making. J Mark Access Health Policy. 2014;2:23740.","journal-title":"J Mark Access Health Policy"},{"issue":"2","key":"1465_CR27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3111\/13696998.2010.491427","volume":"13","author":"A Denis","year":"2010","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295\u2013301.","journal-title":"J Med Econ"},{"issue":"1","key":"1465_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-6-62","volume":"6","author":"C Schey","year":"2011","unstructured":"Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010\u20132020. Orphanet J Rare Dis. 2011;6(1):62.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1465_CR29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13023-022-02534-z","volume":"17","author":"R Lech","year":"2022","unstructured":"Lech R, Chow G, Mann K, Mott P, Malmberg C, Forte L. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025. Orphanet J Rare Dis. 2022;17(1):371.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1465_CR30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10488-015-0661-x","volume":"43","author":"D Hodgkin","year":"2016","unstructured":"Hodgkin D, Thomas CP, O\u2019Brien PL, Levit K, Richardson J, Mark TL, et al. Projected spending on psychotropic medications 2013\u20132020. Adm Policy Ment Health. 2016;43(4):497\u2013505.","journal-title":"Adm Policy Ment Health"},{"issue":"9","key":"1465_CR31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.healthpol.2021.06.008","volume":"125","author":"P Russo","year":"2021","unstructured":"Russo P, Carletto A, N\u00e9meth G, Habl C. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy. 2021;125(9):1140\u20135.","journal-title":"Health Policy"},{"key":"1465_CR32","unstructured":"https:\/\/www.iqvia.com\/. [Internet] c2024. https:\/\/www.iqvia.com\/. Accessed 13 Sept 2024."},{"key":"1465_CR33","unstructured":"EFPIA. 2024. https:\/\/www.efpia.eu\/. Accessed 25 Nov 24."},{"key":"1465_CR34","unstructured":"EMA. 2024. https:\/\/www.ema.europa.eu\/en\/homepage Accessed 25 Nov 24"},{"key":"1465_CR35","unstructured":"ipdanalytics.com. [Internet] c2024. https:\/\/www.ipdanalytics.com\/. Accessed 1 Sept 2024."},{"key":"1465_CR36","doi-asserted-by":"crossref","first-page":"24082","DOI":"10.3402\/jmahp.v2.24082","volume":"2","author":"AL Vataire","year":"2014","unstructured":"Vataire AL, Cetinsoy L, Aballea S, Remuzat C, Urbinati D, Kornfeld A, et al. Novel methodology for pharmaceutical expenditure forecast. J Mark Access Health Policy. 2014;2:24082.","journal-title":"J Mark Access Health Policy"},{"key":"1465_CR37","doi-asserted-by":"crossref","first-page":"23738","DOI":"10.3402\/jmahp.v2.23738","volume":"2","author":"D Urbinati","year":"2014","unstructured":"Urbinati D, Remuzat C, Kornfeld A, Vataire AL, Cetinsoy L, Aballea S, et al. EU pharmaceutical expenditure forecast. J Mark Access Health Policy. 2014;2:23738.","journal-title":"J Mark Access Health Policy."},{"key":"1465_CR38","doi-asserted-by":"crossref","first-page":"27675","DOI":"10.3402\/jmahp.v3.27675","volume":"3","author":"C Remuzat","year":"2015","unstructured":"Remuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3:27675.","journal-title":"J Mark Access Health Policy."},{"issue":"1","key":"1465_CR39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ins.2003.03.023","volume":"170","author":"G Armano","year":"2005","unstructured":"Armano G, Marchesi M, Murru A. A hybrid genetic-neural architecture for stock indexes forecasting. Inf Sci. 2005;170(1):3\u201333.","journal-title":"Inf Sci"},{"issue":"10","key":"1465_CR40","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.cor.2004.06.024","volume":"32","author":"L Yu","year":"2005","unstructured":"Yu L, Wang S, Lai KK. A novel nonlinear ensemble forecasting model incorporating GLAR and ANN for foreign exchange rates. Comput Oper Res. 2005;32(10):2523\u201341.","journal-title":"Comput Oper Res"},{"issue":"4","key":"1465_CR41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neucom.2008.04.017","volume":"72","author":"M Khashei","year":"2009","unstructured":"Khashei M, Bijari M, Raissi Ardali GA. Improvement of auto-regressive integrated moving average models using fuzzy logic and artificial neural networks (ANNs). Neurocomputing. 2009;72(4):956\u201367.","journal-title":"Neurocomputing"},{"issue":"6","key":"1465_CR42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.omega.2004.07.024","volume":"33","author":"P-F Pai","year":"2005","unstructured":"Pai P-F, Lin C-S. A hybrid ARIMA and support vector machines model in stock price forecasting. Omega. 2005;33(6):497\u2013505.","journal-title":"Omega"},{"issue":"2","key":"1465_CR43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0305-0483(01)00062-7","volume":"30","author":"P Goodwin","year":"2002","unstructured":"Goodwin P. Integrating management judgment and statistical methods to improve short-term forecasts. Omega. 2002;30(2):127\u201335.","journal-title":"Omega"},{"key":"1465_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0925-2312(01)00702-0","volume":"50","author":"GP Zhang","year":"2003","unstructured":"Zhang GP. Time series forecasting using a hybrid ARIMA and neural network model. Neurocomputing. 2003;50:159\u201375.","journal-title":"Neurocomputing"},{"key":"1465_CR45","unstructured":"https:\/\/www.orpha.net\/pdfs\/orphacom\/cahiers\/docs\/GB\/Medicinal_products_for_rare_diseases_in_Europe_2023.pdf. Medicinal products for rare diseases in Europe. Orphanet Report Series [Internet]. 2024. https:\/\/www.orpha.net\/pdfs\/orphacom\/cahiers\/docs\/GB\/Medicinal_products_for_rare_diseases_in_Europe_2023.pdf. Accessed 13 Sept 2024."},{"issue":"2","key":"1465_CR46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drudis.2020.11.015","volume":"26","author":"J Ivanovic","year":"2021","unstructured":"Ivanovic J, Capone G, Raffaelli L, Pant\u00f2 V, Marangi M. Horizon Scanning for pharmaceuticals and effective health care programming: 2 years\u2019 experience at the Italian Medicines Agency. Drug Discov Today. 2021;26(2):569\u201376.","journal-title":"Drug Discov Today"},{"key":"1465_CR47","doi-asserted-by":"crossref","unstructured":"Lepage-Nefkens I, Douw K, Mantjes G, de Graaf G, Leroy R, Cleemput I. Horizon scanning for pharmaceuticals: proposal for the BeNeLuxA collaboration: Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE); 2017.","DOI":"10.57598\/R283C"},{"issue":"2","key":"1465_CR48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2018","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2018;20(2):273\u201386.","journal-title":"Biostatistics"},{"key":"1465_CR49","unstructured":"https:\/\/ihsi-health.org\/. [Internet] c2024. https:\/\/ihsi-health.org\/. Accessed 13 Sept 2024."},{"key":"1465_CR50","unstructured":"https:\/\/www.eumonitor.eu\/9353000\/1\/j9vvik7m1c3gyxp\/vlopuzi3zqpj?ctx=vlg6ytug4fga. [Internet] c2021. https:\/\/www.eumonitor.eu\/9353000\/1\/j9vvik7m1c3gyxp\/vlopuzi3zqpj?ctx=vlg6ytug4fga. Accessed 13 Sept 2024."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01465-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:25:30Z","timestamp":1742714730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01465-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01465-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"2 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of the review are employed by the Belgian Health Care Knowledge Centre (KCE). KCE is a governmental institution, funded by the National Institute for Health and Disability Insurance (NIHDI), the Federal Public Service of Health, Food Chain Safety and Environment, and the Federal Public Service of Social Security. KCE\u2019s mission is to advise policymakers on decisions relating to health care and health insurance on the basis of scientific and objective research. The authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest and Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Data collection and analysis were performed by I.O. and I.C. The first draft of the manuscript was written by I.O., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}